XML 81 R4.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDER'S EQUITY - CAD ($)
Class A shares
Class B shares
Warrants
Contributed surplus
Foreign exchange translation reserve
Accumulated Deficit
Total
Beginning balance at Dec. 31, 2017 $ 201,500 $ 12,794,963 $ 2,116,900 $ 1,495,300   $ (4,195,264) $ 12,413,399
Beginning balance (shares) at Dec. 31, 2017 72 3,794,846 354,996        
Shares issued   $ 47,853,745         47,853,745
Shares issued (shares)   2,268,035          
Share issuance costs   $ (6,634,405)         (6,634,405)
Reverse acquisition   $ 9,868,179 $ 118,875 25,725     10,012,779
Reverse acquisition (shares)   545,505 37,313        
Warrant valuations   $ (2,366,670) $ 2,366,670        
Warrant valuations (shares)     198,835        
Share based payments     $ 294,287 6,146,119     6,440,406
Share options exercised   $ 5,145,825   (2,288,775)     2,857,050
Share options exercised (shares)   190,463          
Share options cancelled       (401,069)   401,069  
Warrants exercised   $ 1,254,665 $ (454,587)       800,078
Warrants exercised (shares)   44,931 (44,932)        
Net comprehensive loss for the period           (22,710,624) (22,710,624)
Ending balance at Dec. 31, 2018 $ 201,500 $ 67,916,302 $ 4,442,145 4,977,300   (26,504,819) 51,032,428
Ending balance (shares) at Dec. 31, 2018 72 6,843,780 546,212        
Shares issued   $ 11,539,417         11,539,417
Shares issued (shares)   408,651          
Issued on acquisition of net assets of Prismic Pharmaceuticals, Inc.   $ 16,431,818 $ 1,888,086 2,567,306     20,887,210
Issued on acquisition of net assets of Prismic Pharmaceuticals, Inc. (shares)   510,940 67,598        
Share based payments       16,061,319     16,061,319
Share options exercised   $ 1,782,438   (1,049,840)     732,598
Share options exercised (shares)   130,189          
Warrants exercised   $ 145,174 $ (50,183)       94,991
Warrants exercised (shares)   12,167 (12,167)        
Warrants expired     $ (535,014) 535,014      
Warrants expired (shares)     (134,192)        
Net comprehensive loss for the period         $ (112,690) (52,013,186) (52,125,876)
Ending balance at Dec. 31, 2019 $ 201,500 $ 97,815,149 $ 5,745,034 $ 23,091,099 $ (112,690) $ (78,518,005) $ 48,222,087
Ending balance (shares) at Dec. 31, 2019 72 7,905,727 467,451